The FDA grants Breakthrough Therapy designation to the European company, Compass Pathways, for its psilocybin therapy for treatment-resistant depression.
Resource: Compass Pathways
The FDA grants Breakthrough Therapy designation to the European company, Compass Pathways, for its psilocybin therapy for treatment-resistant depression.
Resource: Compass Pathways